Payment overview · 2025
General Payments
$1,337.53
46 reported records · 19 companies
Healthcare provider profile · identity verified
Richard E White, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · COLORADO SPRINGS, CO · NPI 1528210655
Verified facts
What the public records show
CMS Open Payments records show Richard E White, PA-C received $1,337.53 in general payments during 2025 across 46 reported records.
PFIZER INC. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $284.89 | 21.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $232.78 | 17.4% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $223.13 | 16.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.74 | 7.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $84.35 | 6.3% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $72.69 | 5.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $50.13 | 3.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.97 | 3.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.63 | 3.4% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $31.45 | 2.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.22 | 1.7% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $20.46 | 1.5% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $19.79 | 1.5% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.30 | 1.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.77 | 1.4% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $17.59 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.42 | 1.3% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $16.37 | 1.2% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.85 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,337.53 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $174.15 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $171.99 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $158.61 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $134.50 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $134.50 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $88.63 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $72.69 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $65.35 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.26 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.26 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $50.13 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.97 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.63 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $31.45 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $31.45 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.77 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 495 | 100 |
| Gabapentin | Gabapentin | 272 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 61 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 231 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 119 | 42 |
| Buprenorphine | Buprenorphine | 116 | 32 |
| Lisinopril | Lisinopril | 103 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 29 |
| Pregabalin | Pregabalin | 96 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 41 |
| Losartan Potassium | Losartan Potassium | 81 | 31 |
| Omeprazole | Omeprazole | 77 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 76 | 26 |
| Trazodone Hcl | Trazodone Hcl | 72 | 23 |
| Methocarbamol | Methocarbamol | 71 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 69 | 23 |
| Tramadol Hcl | Tramadol Hcl | 67 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | 18 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Baclofen | Baclofen | 59 | 16 |
| Furosemide | Furosemide | 57 | 16 |
| Clonazepam | Clonazepam | 55 | 11 |
| Metformin Hcl | Metformin Hcl | 55 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 22 |
| Ibuprofen | Ibuprofen | 50 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 19 |
| Lidocaine | Lidocaine | 48 | 16 |
| Xtampza Er | Oxycodone Myristate | 42 | 13 |
| Belbuca | Buprenorphine Hcl | 40 | 12 |
| Methylprednisolone | Methylprednisolone | 40 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 22 |
| Ondansetron Odt | Ondansetron | 36 | 16 |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 34 | 12 |
| Ozempic | Semaglutide | 31 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | 16 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 15 |
| Potassium Chloride | Potassium Chloride | 29 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Famotidine | Famotidine | 19 | 11 |
| Linzess | Linaclotide | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,337.53 · 46 records | PFIZER INC. | ABRYSVO, AIRSUPRA, ARISTADA, AUSTEDO XR, CAPLYTA, CREON, EVENITY, FANAPT, HETLIOZ, INJECTAFER, INSPIRE, JOURNAVX, KRYSTEXXA, Kerendia, LYBALVI, NURTEC ODT, Omnipod, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, Symbravo, UBRELVY, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZTLido | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error